Our Purpose

We improve people’s lives by redefining how medicines and health products are delivered and experienced.

About CURE


Headquartered in Oxnard, California, CURE Pharmaceutical (OTC:CURR) is a fully integrated specialty pharmaceutical/bioscience company that leverages disruptive proprietary drug delivery technologies for a broad range of molecules serving the biopharmaceutical, veterinarian, medical foods and pharmaceutical cannabis markets.


CURE develops its patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today, from its industry leading full service cGMP manufacturing facility. The Company’s mission is to deliver proven drugs in a fast and efficient manner and to improve quality of life

Social Purpose


CURE was founded with the goal of changing the way in which quality medicines are brought to people in need, regardless of geography or economic status. We operate on the principle of social purpose by extending our focus beyond our products and services to maximize our impact on the world. With this originating principle, we founded Oak Therapeutics, a wholly owned subsidiary of CURE focused on bringing life-saving medicines to developing economies.


Robert Davidson  |  CEO and Chairman of the Board of Directors

Prior to his role at CURE Pharmaceutical, Robert Davidson served as President and Chief Executive Officer of InnoZen Inc., Chief Executive Officer of Gel Tech LLC, Chief Executive Officer of Bio Delivery Technologies Inc., and has served on multiple corporate boards.  Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has worked with brands such as Chloraseptic™, Suppress™, as well as Pediastrip™, a private label electrolyte oral thin film sold in major drug store chains. Davidson received his B.S. degree with a concentration in Biological Life Sciences. He has a Masters Certificate in Applied Project Management from Villanova University, Masters of Public Health from American Military University, Virginia and a Masters in Health and Wellness from Liberty University, Virginia. Davidson also attended Post Graduate Studies at the University of Cambridge.

Edward Maliski, PhD  |  President and Chief Science Officer

Dr. Edward Maliski is an accomplished research scientist with 30 years of experience in the development of pharmaceutical and biotechnology products. As an executive leader and strategist, Maliski contributed his expertise in project management and chemical research to facilitate the transfer of new discoveries into pharmaceutical products for the Sterling Winthrop Research Institute, Glaxo Research Institute, Merck & Co., and Amgen Inc. Additionally, Dr. Maliski has worked with several successful start-up companies.

Wayne Nasby  |  Chief Operations Officer

As Chief Operating Officer, Wayne leads the executive management team to focus on the development and commercialization of innovative and technically complex pharmaceutical products.  Wayne has been recognized by industry and regulatory leaders in cGMP pharmaceutical regulatory compliance and innovation.  He has successfully built pharmaceutical manufacturing facilities in Asia, Europe and the United States. With more than 30 years’ experience in the biotechnology and pharmaceutical industry, Wayne has held a variety of roles within the areas of corporate quality, supply chain management, manufacturing, process development and project management.  Prior to CURE, he served as Vice President of Operations at Innozen Inc. where he was responsible for commercial manufacturing locations, quality assurance and Innozen’s supply chain. Wayne also served early on in various leadership positions at AMGEN, Inc. where he was instrumental in helping build the industry’s largest Biotechnology company.  During his twenty-year tenure at AMGEN, Inc. he was responsible for the distribution and transportation of bulk and commercial biotechnology products within the United States and to Asia, Australia, Europe and Puerto Rico.

Jessica Rousset  | Chief Business Officer

As Chief Business Officer, Jessica has responsibility for driving strategy and growth. She is a seasoned business development and commercialization leader, expert in bridging corporate, academic and governmental interests toward the common goal of improving patient’s lives. She brings more than fifteen years of experience fostering innovation in large organizations and advising start-ups to bring novel healthcare solutions to market and into clinical use. Jessica previously served as Head of Innovation at Children’s Hospital Los Angeles, where over a ten year period, she helped launch both therapeutic and medical device companies and founded and operated a national pediatric technology accelerator. Prior to that, Jessica held positions at The Scripps Research Institute and GlaxoSmithkline Biologicals in laboratory, clinical research and business development roles. She trained as a biochemical engineer at the Institut National des Sciences Appliquées in Lyon, France.

Mark Udell  |  Chief Financial Officer

Mark Udell has served as the Chief Financial Officer, Treasurer and Secretary of CURE Pharmaceutical since July 2011.  He is a Certified Public Accountant with over 17 years of experience in finance and accounting. Prior to Cure Pharmaceutical, Udell served as InnoZen, Inc.’s Chief Accounting Officer and Controller. He has also held the position as Auditing Manager at Green Hasson & Janks, LLP in Los Angeles. Mr. Udell received his B.A. in Business Economics with a concentration in accounting from the University of California, Santa Barbara.

Eric E. Allen, PhD  |  Director of Research and Development

Dr. Eric Allen brings over 25 years of pharmaceutical industry experience to CURE Pharmaceutical. Allen spent 10 years at Merck & Co, where he synthesized and patented heterocyclic drug molecules. He later devoted himself to chemical information management for Amgen Inc., where he was involved in all aspects of scientific database and software design. Allen is a recognized expert in the pharmaceutical industry for his programming, design, and insight in the drug discovery field, and is an inventor on 16 drug-related, issued U.S. patents.

Richard Serbin  |  Director of Corporate Development

Mr. Richard S. Serbin is a global strategy advisor and entrepreneur with credentials both in pharmacy and law, complemented by more than 40 years of service as an FDA regulatory attorney and patent attorney in the healthcare industry. Mr. Serbin is an expert in licensing medical extracts, compounds, and technologies. He is a pharmacist and patent attorney with more than 25 years of experience in the pharmaceutical industry and the investment community.  Mr. Serbin spent a large portion of his career focusing on international markets and clients.

William Yuan  |  Director

William Yuan was most recently Chairman and CEO of Fortress Hill Holdings, an Asian-based investment banking firm. With 23 years in global finance experience, he has served as a key strategist and advisor to international institutions. U.S. companies advised by Mr. Yuan include Amgen Corp., Biogen, GE Capital, Warner Brothers Studios, and Fox News. He has also guided such leading Asian institutions as Sina.com, Shanghai Petrochemicals, Jinlia Pharmaceutical and Tsingtao Beer Corp. In 1995, Mr. Yuan led Merrill Lynch Asset Management Asia, and managed one of the largest pension/retirement funds in the world, with a $488 billion portfolio under his leadership. Simultaneously, he was chairman and portfolio manager of the $1.2 billion AmerAsia Hedge Fund. In 1993, he was the founder and managing director of the Corporate Institutional Services Group at Merrill Lynch Asset Management. Prior to that, Mr. Yuan served as a senior-vice president and co-manager at Morgan Stanley Smith Barney’s Portfolio Management Corporation with dual functions as co-head of the Capital Markets Derivative team, and Chairman of the Technology Investment Management and Executive Policy Committee. He began his finance career at Goldman Sachs in 1983 as an investment banker in Mergers & Acquisitions. Mr. Yuan is a member of the International Who’s Who of Finance, Technology, Media and Telecom. Mr. Yuan holds a Bachelor of Science degree in Economics from Cornell University and attended Harvard University’s John F. Kennedy School as a Mason Fellow.

Charles Berman  |  Director

Formerly a shareholder at Greenberg Traurig LLP, and partner at other leading law firms including Merchant and Gould, Charles Berman has focused his practice in patent work for more than 40 years. His clients include both major corporations and smaller companies, which he represents within the U.S. and internationally. He has a degree in electrical engineering and a law degree from the University of Witwatersrand in Johannesburg, where he also started his legal career, concentrating in patent work. In 1978 Berman joined Lyon & Lyon’s Los Angeles office as an associate, and he has remained in the U.S. ever since. HeHe is admitted to practice before the United States Supreme Court, the US Patent and Trademark Offices, the US District Court, Central District of California. From 1996-2000, he served as president, secretary and treasurer of the Los Angeles Intellectual Property Law Association (“LAIPLA”), and has represented LAIPLA and the California State Bar Intellectual Property Section before the U.S. Bar/European Patent Office- Liaison Council and the U.S. Bar/Japanese Patent Office- Liaison Council since 1990. Berman also has been a member of the Editorial Board of Managing Intellectual Property magazine since 1992. A board member of the American Intellectual Property Association form 1995 to 1998, he was a founding fellow of the AIPLA.

Alan Einstein, MD  |  Director

Dr. Alan Einstein, grandson to famed Albert Einstein, has been practicing medicine since 1996. His educational history includes a Bachelors of Science undergraduate degree in Physical Chemistry from The University of Florida. Subsequently, he earned his medical degree from The College of Osteopathic Medicine and Surgery in Des Moines, Iowa, in 1992. Subsequently, Dr. Einstein completed his Internship and Residency training at The Johns Hopkins University School of Medicine/Sinai Hospital program in Internal Medicine, in Baltimore, MD in 1995, where he was recognized as, “The Outstanding Senior Resident of the Year.” Dr. Einstein is also involved in medical research utilizing Umbilical Cord Blood stem cells, with a particular interest in Parkinson’s disease. Dr. Einstein also assisted Senator David Shafer in the writing and passage of Georgia’s first and only Cord Blood stem cell bill. Furthermore, in July 2006, Georgia’s Governor Sonny Perdue appointed Dr. Einstein to the, “Commission for Newborn Umbilical Cord Blood Research and Medical Treatment.” He emphasizes health and preventative care to allow individuals to achieve their maximum potential. He has numerous areas of medical expertise including cardiovascular diseases, diabetes, thyroid and hormone metabolism disorders. He emphasizes returning adults to a normal hormonal state, yet via a more natural route. Furthermore, Dr. Einstein is a thought leader in the area of metabolic syndrome and its role in weight gain and overall health and longevity. He has presented to his medical peers at numerous medical institutions and conferences around the country, and has been featured on Video Health Magazine and Diabetes News Stand.Dr. Einstein prides himself in individualized and unrushed medical care. He takes detailed histories and performs thorough physical examinations while paying attention to detail.

Greg Strathe, DVM 

Dr. Strathe has been a practicing veterinarian for over 20 years. He is co-owner of one of the largest animal hospitals in Oklahoma. Dr. Strathe’s interests include internal medicine, surgery, dentistry, and overall preventative health of his patients. Dr. Strathe has been involved with Cure Pharmaceutical the past 2 years. He has tested numerous products and compliance with his patients using the strip technology and delivery system. Dr. Strathe Graduated KSU vet school in 1993, Bachelors in Arts & Science KSU 1998.

Michael Neely, MD

 Dr. Neely is the director of the University of Southern California Laboratory of Applied Pharmacokinetics, which has been at the forefront of nonparametric population pharmacokinetic modeling techniques and dose optimization for individual patients for over 35 years. He is an Associate Professor of Pediatrics, Clinical Scholar at the University of Southern California (USC) and at Children’s Hospital Los Angeles. His research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and most importantly, use of models to optimize therapy for individual patients. He has a Master of Science degree in Clinical and Biomedical Investigations from USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling. He is a member of the United States Food and Drug Administration Anti-­infective Drug Advisory Committee and board certified in pediatrics, pediatric infectious diseases and a Fellow of the American College of Clinical Pharmacology. He completed a four-year NIH career development award, and is the Principle Investigator for two R01 awards from the NIH totaling over 6 million dollars over 5 years to develop and apply pharmacometric techniques to anti-infective therapy in populations and individual patients. Dr. Neely has over 50 publications in peer-reviewed journals, and is invited to give talks and workshops on dose individualization and optimization worldwide.


Ian Sephton 

Ian Sephton is currently the CEO of Syncromatics, a SaaS and technology integration company disrupting the mobility market. Prior to that role he Co-Founded Hangar202 an early stage investment firm and The Branstetter Group a retail hospitality ideation firm. With over 20 years of C-level experience in retail and technology markets, Ian currently sits on the board of 5 private companies and Cure Pharmaceutical a publicly traded drug delivery technology company. Ian remains active in social causes tied to veteran rights and homelessness in Downtown Los Angeles. As a former Marine and serial entrepreneur Ian believes a company without a social mission is a ship without a compass. He believes strongly that the technology developed by Cure Pharmaceutical can improve lives and is dedicated to supporting the company with his diverse leadership experience and strategic marketing expertise. Ian earned his undergraduate degree from California Lutheran University and sits on the business school advisory board. He earned his MBA from the University of Southern California.